POCP Blog

Electronic Prior Authorization Being Brought into Pharmacists’ Workflow

By Jocelyn Keegan, Senior Consultant With recent legislative changes and maturity in the industry, pharmacists will soon be enabled to electronically initiate and handle pre-approval—or prior authorization (PA) — directly …

Improving Care Quality using ePrescribing: CancelRx

Electronic prescribing (ePrescribing) is ubiquitous, but there is still room for improvement. Many, including RAND researchers, put the CancelRx transaction at the top of the list, because of its implications for …

How Pharmaceutical Companies Could be Affected by the AMA’s Prior Authorization and Utilization Management Reform Proposal

Prior authorization (PA) for medications, devices and services is viewed as a valuable utilization management tool by payers but is a long-standing pain point for providers, pharmacists and the pharmaceutical …

Why Pharmaceutical Companies Need to Invest in Population Health Management

Investing in population health management programs (PHMs) is becoming increasingly important for pharmaceutical manufacturers. Amidst the uncertainty of health reform, we can still count on payers pushing ahead in their efforts to contract with …

5 Ways the AMA’s 21 Prior Authorization Principles Impact Electronic Health Records

By Michael Burger Recently a multi-stakeholder consortium led by the American Medical Association (AMA) published a white paper entitled “Prior Authorization and Utilization Management Reform Principles.” This paper identifies 21 …

How Health IT Can Help Payers Address Prior Authorization Reform, Advance Electronic Prior Authorization

By Jocelyn Keegan Prior authorization (PA) for medications, devices and therapies is viewed as a valuable utilization management tool by payers but a long-standing pain point for providers and pharmacists. …

FDA Issues Guidance on Naming Conventions and Interchangeability for Biologics and Biosimilars

By Pooja Babbrah, Senior Consultant The Food and Drug Administration (FDA) recently issued two new rules that significantly affect biologics and biosimilars.  The first rule spells out the naming conventions …

The 21st Century Cures Act and Health IT: A Birds’ Eye View

By Tony Schueth The 21st Century Cures Act is now the law of the land. As you’ve probably heard by now, this bipartisan, $6.3 billion piece of legislation is intended …

A Practical Approach to Implementing a Population Health Management Program

By Michael Solomon Whenever I engage in discussion with health care executives or clinicians about strategies and programs for population health management (PHM), we have to step back and invest …

5 Ways the Trump Presidency May Impact ONC

In a post on November 14, we laid out our view of the implications of an unexpected Trump victory on healthcare, in general, and health information technology (health IT), specifically …